BioCentury | Mar 13, 2021
Product Development

Manufacturing resilience: antibody developers adapt to supply-demand shifts

...materials.” Genmab and partner Seagen Inc. (NASDAQ:SGEN) (formerly Seattle Genetics...
BioCentury | Mar 9, 2021
Product Development

New modality deep dive; plus Sharpless speaks & Five Prime scores: a BioCentury podcast

...Kadcyla ado-trastuzumab emtansine from Roche (SIX:ROG; OTCQX:RHHBY) and Adcetris brentuximab vedotin from  Seagen Inc. (NASDAQ:SGEN) (formerly Seattle Genetics Inc....
BioCentury | Mar 6, 2021
Product Development

The pace of new modality approvals is picking up

...new modality.Moreover, while Seagen Inc. (NASDAQ:SGEN) (formerly Seattle Genetics Inc....
BioCentury | Dec 8, 2020
Product Development

ADC and ROR1 momentum grows with ASH data behind Merck, VelosBio deal

...billion up front in a September deal with Seattle Genetics Inc....
BioCentury | Sep 24, 2020
Finance

Sept. 23 Quick Takes: Zai raises $776M, Silverback $85M; plus Novartis, PureTech, UCB and more

...new shares in the process.Padcev meets urothelial cancer endpointPadcev enfortumab vedotin-ejfv from Astellas Pharma Inc. (Tokyo:4503) and Seattle Genetics Inc....
BioCentury | Sep 15, 2020
Deals

With $1.7B in Merck deals, Seattle Genetics plots broader pipeline

...Merck deals give Seattle Genetics $725M in cash, $1B...
...over Seattle Genetics’ close of $149.97 on Friday. Seattle Genetics...
...the program.” Clay Siegall, Seattle Genetics Merck and Seattle Genetics...
BioCentury | Sep 15, 2020
Deals

$21B deal by Gilead, none by PhRMA: a BioCentury podcast

...nearly 40 years as an independent company, $1.5 billion raised and a scuttled deal with Seattle Genetics...
...deal to start the week and another breast cancer deal, we have Merck partnering with Seattle Genetics...
...some ambiguity. And then this program was the center of a deal with another company Seattle Genetics...
BioCentury | Sep 14, 2020
Deals

High takeout premium in $21B deal shows Gilead’s confidence in value of Immunomedics’ ADC

...issues.Nearly two years prior, a deal granting Seattle Genetics Inc....
BioCentury | Sep 9, 2020
Product Development

Networking that fueled COVID-19 response should spill into digital sciences and more, says Genmab’s van de Winkel: a BioCentury audio interview

...of that program. Yes, we are doing that massively. We're also doing it together with Seattle Genetics...
BioCentury | Jul 10, 2020
Regulation

Ocular toxicity assessment stands between multiple myeloma patients and the first BCMA approval

...populations, so a bystander effect is possible. Last year, FDA approved Padcev enfortumab vedotin-ejfv from Seattle Genetics Inc....
Items per page:
1 - 10 of 858
BioCentury | Mar 13, 2021
Product Development

Manufacturing resilience: antibody developers adapt to supply-demand shifts

...materials.” Genmab and partner Seagen Inc. (NASDAQ:SGEN) (formerly Seattle Genetics...
BioCentury | Mar 9, 2021
Product Development

New modality deep dive; plus Sharpless speaks & Five Prime scores: a BioCentury podcast

...Kadcyla ado-trastuzumab emtansine from Roche (SIX:ROG; OTCQX:RHHBY) and Adcetris brentuximab vedotin from  Seagen Inc. (NASDAQ:SGEN) (formerly Seattle Genetics Inc....
BioCentury | Mar 6, 2021
Product Development

The pace of new modality approvals is picking up

...new modality.Moreover, while Seagen Inc. (NASDAQ:SGEN) (formerly Seattle Genetics Inc....
BioCentury | Dec 8, 2020
Product Development

ADC and ROR1 momentum grows with ASH data behind Merck, VelosBio deal

...billion up front in a September deal with Seattle Genetics Inc....
BioCentury | Sep 24, 2020
Finance

Sept. 23 Quick Takes: Zai raises $776M, Silverback $85M; plus Novartis, PureTech, UCB and more

...new shares in the process.Padcev meets urothelial cancer endpointPadcev enfortumab vedotin-ejfv from Astellas Pharma Inc. (Tokyo:4503) and Seattle Genetics Inc....
BioCentury | Sep 15, 2020
Deals

With $1.7B in Merck deals, Seattle Genetics plots broader pipeline

...Merck deals give Seattle Genetics $725M in cash, $1B...
...over Seattle Genetics’ close of $149.97 on Friday. Seattle Genetics...
...the program.” Clay Siegall, Seattle Genetics Merck and Seattle Genetics...
BioCentury | Sep 15, 2020
Deals

$21B deal by Gilead, none by PhRMA: a BioCentury podcast

...nearly 40 years as an independent company, $1.5 billion raised and a scuttled deal with Seattle Genetics...
...deal to start the week and another breast cancer deal, we have Merck partnering with Seattle Genetics...
...some ambiguity. And then this program was the center of a deal with another company Seattle Genetics...
BioCentury | Sep 14, 2020
Deals

High takeout premium in $21B deal shows Gilead’s confidence in value of Immunomedics’ ADC

...issues.Nearly two years prior, a deal granting Seattle Genetics Inc....
BioCentury | Sep 9, 2020
Product Development

Networking that fueled COVID-19 response should spill into digital sciences and more, says Genmab’s van de Winkel: a BioCentury audio interview

...of that program. Yes, we are doing that massively. We're also doing it together with Seattle Genetics...
BioCentury | Jul 10, 2020
Regulation

Ocular toxicity assessment stands between multiple myeloma patients and the first BCMA approval

...populations, so a bystander effect is possible. Last year, FDA approved Padcev enfortumab vedotin-ejfv from Seattle Genetics Inc....
Items per page:
1 - 10 of 858